


INFORMATION DISCLOSURE STATEMENT (37 C.F.R. 1.56, 1.97, and 1.98)	ATTORNEY DOCKET	APPLICATION NO.
	23164-1002	08/853,29 ² ₈
	APPLICANT(S) Tovey, Michael G.	
SHEET 1 OF 1	May 9, 1997	GROUP
		1642 1646

U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)



FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #				TRANSLATION (YES/NO)
	1	WO 82/00588	4/82	PCT	
	2	WO 92/10207	8/92	PCT	
	3	0 396 903	3/90	EPO	

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	4	Hayden, Frederick G., "Intranasal Interferon α2 for Prevention of Rhinovirus Infection and Illness", The Journal of Infectious Diseases, Vol. 148, No. 3 September 1983, pp. 543-550.

IDS DOES NOT COMPLY WITH 37 CFR § 1.97(d).

EXAMINER'S SIGNATURE DAVID L. FITZGERALD PRIMARY EXAMINER GROUP 1800	DATE CONSIDERED 6/29/99
-------------------------------------------------------------------------------------------------	----------------------------

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

FILE